Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Hiromichi Ito

ORCID-verified (high confidence, 0.95), identity_conf@1As of 9 November 2026

Matched on ORCID iD 0000-0003-0941-2055; OpenAlex author ID A5030164112. Sources: OpenAlex.

Their work

Papers
52 (first author 8, last author 8)
Trials
0
Grants
0
Labs led
2
Collaborators
69
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 1 paper · 2015: 3 papers · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: 2 papers · 2020: 4 papers · 2021: 3 papers · 2022: 10 papers · 2023: 11 papers · 2024: 3 papers · 2025: 11 papers · 2026: 1 paper

Papers 50 of 52

  1. Surgical Challenges Associated with Collateral Veins Formation in Pancreatic Cancer with Vein Resection. Co-author DOI 10.1245/s10434-025-18806-4↗
  2. Anatomical evaluation of the perinephric vein as a surgical landmark in minimally invasive distal pancreatectomy for pancreatic cancer. Co-author DOI 10.1007/s00464-025-12125-1↗
  3. Clinical implications of disappearing pancreatic cancer liver metastases: Lessons from colorectal liver metastases. Co-author DOI 10.1016/j.ejso.2025.109635↗
  4. Exploring the role of CA 19-9 dynamics in pancreatic cancer multidisciplinary treatment: Proposal of the PANC classification. Co-author DOI 10.1016/j.surg.2025.109783↗
  5. Arterial resection and divestment in pancreatic cancer surgery in the era of multidisciplinary treatment: decadal comparative study. Co-author DOI 10.1093/bjsopen/zraf026↗
  6. Editor's Note: A Novel Role for Carcinoembryonic Antigen-Related Cell Adhesion Molecule 6 as a Determinant of Gemcitabine Chemoresistance in Pancreatic Adenoca… First author DOI 10.1158/0008-5472.can-25-0886↗
  7. Retraction: Prostaglandin E2 Enhances Pancreatic Cancer Invasiveness through an Ets-1-Dependent Induction of Matrix Metalloproteinase-2. Co-author DOI 10.1158/0008-5472.can-25-0887↗
  8. Editor's Note: RNA Interference Demonstrates a Novel Role for Integrin-Linked Kinase as a Determinant of Pancreatic Adenocarcinoma Cell Gemcitabine Chemoresist… First author DOI 10.1158/1078-0432.ccr-25-0820↗
  9. Technique of Circumferential Divestment of the Superior Mesenteric Artery for Locally Advanced Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-17019-z↗
  10. ASO Author Reflections: Advancing the Superior Mesenteric Arterial Divestment for Locally Advanced Pancreatic Cancer: New Standard Procedure and Future Prospec… Co-author DOI 10.1245/s10434-025-17090-6↗
  11. Resectable Pancreatic Cancer with CA19-9 > 500 U/mL: A Biological Indicator for Survival Benefit with Intensive Neoadjuvant Chemotherapy. Co-author DOI 10.1245/s10434-025-17407-5↗
  12. ASO Author Reflections: Optimizing Treatment for Resectable Pancreatic Cancer: CA19-9 > 500 U/mL as a Biologic Indicator for Neoadjuvant Therapy. Co-author DOI 10.1245/s10434-025-17458-8↗
  13. Caveolin-1 expression is a predictor of survival and recurrence patterns in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2024.10.001↗
  14. A proposal of ABCD metastasectomy criteria for synchronous/metachronous metastatic pancreatic cancer in the era of multidisciplinary treatment. Co-author DOI 10.1093/bjs/znad417↗
  15. Unique Biology of Pancreatic Ductal Adenocarcinoma Accompanied by Rapidly Impaired Diabetes: A Favorable Long-Term Survival Following Curative Resection. Co-author DOI 10.1245/s10434-023-14408-0↗
  16. Feasibility of laparoscopic radical antegrade modular pancreatosplenectomy (RAMPS) as a standard treatment for distal resectable pancreatic cancer. Co-author DOI 10.1007/s00423-023-02942-0↗
  17. New approach of circumferential lymph node dissection around the superior mesenteric artery for pancreatic cancer during pancreaticoduodenectomy (with video). Co-author DOI 10.1007/s00423-023-03159-x↗
  18. Radical antegrade modular pancreatosplenectomy enhances local control of the disease in patients with left-sided pancreatic cancer. Co-author DOI 10.1016/j.hpb.2022.08.004↗
  19. Analysis of prognostic factors for borderline resectable pancreatic cancer after neoadjuvant chemotherapy: the importance of CA19-9 decrease in patients with e… Co-author DOI 10.1016/j.hpb.2022.09.012↗
  20. Intraoperative paraaortic lymph node sampling during resection for pancreatic cancer: evolving role in the modern chemotherapy era. Last author DOI 10.1016/j.hpb.2023.05.366↗
  21. Withdrawal: CEACAM6 cross-linking induces caveolin-1-dependent, Src-mediated focal adhesion kinase phosphorylation in BxPC3 pancreatic adenocarcinoma cells. First author DOI 10.1016/j.jbc.2023.105007↗
  22. Retraction notice to Retrovirally mediated RNA interference targeting the M2 subunit of ribonucleotide reductase (RRM2): a novel therapeutic strategy in pancre… First author DOI 10.1016/j.surg.2023.01.008↗
  23. Retraction Note: RNA interference targeting the M2 subunit of ribonucleotide reductase enhances pancreatic adenocarcinoma chemosensitivity to gemcitabine. First author DOI 10.1038/s41388-023-02627-4↗
  24. Editorial Expression of Concern: Overexpression of CEACAM6 promotes insulin-like growth factor I-induced pancreatic adenocarcinoma cellular invasiveness. First author DOI 10.1038/s41388-023-02784-6↗
  25. Clinical Efficacy of Neoadjuvant Chemotherapy with Gemcitabine plus S-1 for Resectable Pancreatic Ductal Adenocarcinoma Compared with Upfront Surgery. Co-author DOI 10.1245/s10434-023-13534-z↗
  26. Impact of sarcopenia on S1 adjuvant chemotherapy and prognosis in pancreatic cancer patients. Co-author DOI 10.5582/bst.2023.01209↗
  27. Long-Term Outcome of Patients with Postoperative Refractory Diarrhea After Tailored Nerve Plexus Dissection Around the Major Visceral Arteries During Pancreato… Co-author DOI 10.1007/s00268-022-06457-5↗
  28. Diabetogenic liver metastasis from pancreatic cancer: a case report. Co-author DOI 10.1186/s40792-022-01582-8↗
  29. Impact of Tumor Size on the Outcomes of Patients with Resectable Distal Pancreatic Cancer: Lessons Learned from a Series of 158 Radical Resections. Last author DOI 10.1245/s10434-021-10560-7↗
  30. ASO Author Reflections: Size Matters in Distal Pancreatic Cancer: Predictor for Failure of Upfront Resection for Radiologically Resectable Disease. Co-author DOI 10.1245/s10434-021-10686-8↗
  31. Laparoscopic Radical Antegrade Modular Pancreatosplenectomy with Anterocranial Splenic Artery-First Approach for Left-Sided Resectable Pancreatic Cancer (with … Co-author DOI 10.1245/s10434-022-11382-x↗
  32. Prediction of Recurrence Pattern of Pancreatic Cancer Post-Pancreatic Surgery Using Histology-Based Supervised Machine Learning Algorithms: A Single-Center Ret… Co-author DOI 10.1245/s10434-022-11471-x↗
  33. Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOL… Co-author DOI 10.1245/s10434-022-11503-6↗
  34. ASO Author Reflections: Histology-Based Supervised Machine Learning Model Can Predict Recurrence Pattern of Pancreatic Cancer. Co-author DOI 10.1245/s10434-022-11540-1↗
  35. ASO Author Reflections: What are the Indications for Conversion Surgery for Initially Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcit… Co-author DOI 10.1245/s10434-022-11621-1↗
  36. Response: Impact of Tumor Size on Outcomes for Patients with Resectable Distal Pancreatic Cancer. First author DOI 10.1245/s10434-022-11841-5↗
  37. High CA19-9 level in resectable pancreatic cancer is a potential indication of neoadjuvant treatment. Co-author DOI 10.1016/j.pan.2020.11.026↗
  38. C646 inhibits G2/M cell cycle-related proteins and potentiates anti-tumor effects in pancreatic cancer. Co-author DOI 10.1038/s41598-021-89530-8↗
  39. Staging laparoscopy for pancreatic cancer using intraoperative ultrasonography and fluorescence imaging: the SLING trial. Co-author DOI 10.1093/bjs/znaa111↗
  40. Regional pancreatoduodenectomy versus standard pancreatoduodenectomy with portal vein resection for pancreatic ductal adenocarcinoma with portal vein invasion. First author DOI 10.1002/bjs5.50268↗
  41. Radiologically occult metastatic pancreatic cancer: how can we avoid unbeneficial resection? Co-author DOI 10.1007/s00423-019-01846-2↗
  42. Three-Dimensional Fixation: Pathological Protocol Following Pancreaticoduodenectomy with Portal Vein Resection for Pancreatic Cancer. Co-author DOI 10.1007/s11605-019-04203-2↗
  43. Commentary: Complex venous resection and reconstruction for locally advanced pancreatic cancer: Our approach. Co-author DOI 10.1016/j.surg.2020.08.003↗
  44. Optimal Extent of Superior Mesenteric Artery Dissection during Pancreaticoduodenectomy for Pancreatic Cancer: Balancing Surgical and Oncological Safety. Last author DOI 10.1007/s11605-018-3995-3↗
  45. Techniques for splenic vein reconstruction after pancreaticoduodenectomy with portal vein resection for pancreatic cancer. Co-author DOI 10.1016/j.hpb.2019.01.017↗
  46. Asymptomatic Pancreatic Cancer: Does Incidental Detection Impact Long-Term Outcomes? Last author DOI 10.1007/s11605-017-3421-2↗
  47. P300 inhibition enhances gemcitabine-induced apoptosis of pancreatic cancer. Last author DOI 10.18632/oncotarget.10117↗
  48. Biweekly gemcitabine plus S-1 for locally advanced and metastatic pancreatic cancer: a preliminary feasibility study. Co-author DOI 10.1002/jhbp.274↗
  49. PTK6 Potentiates Gemcitabine-Induced Apoptosis by Prolonging S-phase and Enhancing DNA Damage in Pancreatic Cancer. Last author DOI 10.1158/1541-7786.mcr-15-0034↗
  50. Efficacy of Neoadjuvant Versus Adjuvant Therapy for Resectable Pancreatic Adenocarcinoma: A Decision Analysis. Last author DOI 10.1245/s10434-015-4711-0↗

Closest collaborators

The 25 strongest of 69 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Atsushi Oba · 30 shared papers, 2019–2026 · strength 5.42
  2. Yu Takahashi · 31 shared papers, 2017–2025 · strength 5.02
  3. Yosuke Inoue · 29 shared papers, 2017–2025 · strength 4.78
  4. Yoshihiro Ono · 28 shared papers, 2019–2026 · strength 4.75
  5. Akio Saiura · 18 shared papers, 2019–2024 · strength 2.71
  6. Masato Ozaka · 11 shared papers, 2022–2026 · strength 2.02
  7. Naoki Sasahira · 11 shared papers, 2022–2026 · strength 2.02
  8. Edward E. Whang · 8 shared papers, 2015–2025 · strength 1.90
  9. Mark S. Duxbury · 7 shared papers, 2023–2025 · strength 1.83
  10. Stanley W. Ashley · 7 shared papers, 2023–2025 · strength 1.83
  11. Aya Maekawa · 8 shared papers, 2024–2026 · strength 1.65
  12. Manabu Takamatsu · 8 shared papers, 2022–2025 · strength 1.48
  13. Takashi Sasaki · 8 shared papers, 2022–2026 · strength 1.38
  14. Yoshihiro Ono · 6 shared papers, 2023–2025 · strength 1.25
  15. Kojiro Omiya · 6 shared papers, 2024–2025 · strength 1.21
  16. Takafumi Mie · 6 shared papers, 2022–2025 · strength 1.17
  17. Genki Watanabe · 4 shared papers, 2022–2023 · strength 0.89
  18. Tomotaka Kato · 5 shared papers, 2021–2026 · strength 0.89
  19. Yosuke Inoue · 4 shared papers, 2024–2026 · strength 0.77
  20. Yu Takahashi · 3 shared papers, 2025 · strength 0.74
  21. Yuki Hirose · 4 shared papers, 2024–2025 · strength 0.74
  22. Yu Takahashi · 3 shared papers, 2025–2026 · strength 0.71
  23. Yuta Ushida · 4 shared papers, 2021–2022 · strength 0.57
  24. Ryota Ito · 2 shared papers, 2025 · strength 0.54
  25. Tsuyoshi Takeda · 3 shared papers, 2023–2024 · strength 0.49

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.